8th Annual RNAi-Based Therapeutics Summit

8th Annual RNAi-Based Therapeutics Summit is organized by Hanson Wade and will be held from Jan 27 - 29, 2027 at Homewood Suites by Hilton Boston Seaport District, Boston, Massachusetts, United States of America.

Description:
Advancing Extrahepatic RNAi Delivery to Improve Targeting Selectivity Across Obesity, Metabolic, Cardiovascular, Neurology & Oncology
With major pharma investments, billion-dollar partnerships, and promising clinical progress launched the RNAi field into a new era of growth, there is a race to be the first to unveil the full potential of RNAi as a transformative therapeutic modality.

Now, the biggest challenge for biopharma remains centred on optimizing delivery, as the industry strives to bring these innovative and life-changing RNAi therapies to wider patient populations.

For 2027, the 8th RNAi-Based Therapeutics Summit returns to unite the leaders driving this momentum to explore the next frontier of RNAi development to overcome the challenge of extra-hepatic delivery across high-value indications like neurology, cardiometabolic disease, obesity, cardiovascular disease, and oncology and more.

Providing the ultimate platform for RNAi drug developers to come together and work together in interactive workshops, hear from experts in panels, and explore new data from our expert speakers to accelerate the development of more potent and safer RNAi drugs.

Join experts from Eli Lilly, Bayer, Canary Cure, Thalia Therapeutics and more to be part of the mission to usher in the future of RNAi therapeutics

Explore the Full Event Guide:

• Learn from 20+ expert speakers from leading biotech and pharma companies including Eli Lilly, Bayer, Thalia Therapeutics, & Canary Cure
• Explore the newest insights into data covering extrahepatic RNAi delivery, CNS, cardiovascular, obesity, retinal & oncology applications, as well as applications of miRNA technology
• Gain practical insights into funding, partnerships & clinical translation strategies
• Create connections with top RNAi decision-makers through dedicated networking sessions with 80+ industry leaders